CDI 988
Alternative Names: CDI-988Latest Information Update: 30 Dec 2025
At a glance
- Originator Cocrystal Pharma Inc
- Class Antivirals; Small molecules
- Mechanism of Action 3C viral protease inhibitors; Coronavirus 3C-like proteinase inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I COVID 2019 infections; Norovirus infections
Most Recent Events
- 18 Dec 2025 Cocrystal Pharma receives approval from the Institutional Review Board (IRB) to initiate a phase Ib human challenge study with CDI 988
- 14 Nov 2025 Cocrystal Pharma plans a phase Ib/II human challenge study for Norovirus infections (In Volunteers) in USA in the first quarter 2026 (PO) (NCT07198139)
- 12 Sep 2025 US FDA approves IND application for CDI 988 for prevention and treatment of Norovirus infection, prior to September 2025